108 related articles for article (PubMed ID: 25174623)
41. Factors predictive of elevated serum CA125 levels in patients with epithelial ovarian cancer.
Bouanène H; Harrabi I; Ferchichi S; Ben Limem H; Miled A
Bull Cancer; 2007 Jul; 94(7):E18-22. PubMed ID: 17723943
[TBL] [Abstract][Full Text] [Related]
42. The effect of CA125 on metastasis of ovarian cancer: old marker new function.
Yuan Q; Song J; Yang W; Wang H; Huo Q; Yang J; Yu X; Liu Y; Xu C; Bao H
Oncotarget; 2017 Jul; 8(30):50015-50022. PubMed ID: 28637006
[TBL] [Abstract][Full Text] [Related]
43. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.
Simon I; Zhuo S; Corral L; Diamandis EP; Sarno MJ; Wolfert RL; Kim NW
Cancer Res; 2006 Feb; 66(3):1570-5. PubMed ID: 16452214
[TBL] [Abstract][Full Text] [Related]
44. The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer.
Lee YJ; Kim Y; Choi BB; Kim JR; Ko HM; Suh KH; Lee JS
BMC Cancer; 2022 Jan; 22(1):12. PubMed ID: 34979986
[TBL] [Abstract][Full Text] [Related]
45. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer.
Le Page C; Ouellet V; Madore J; Hudson TJ; Tonin PN; Provencher DM; Mes-Masson AM
Int J Cancer; 2006 Apr; 118(7):1750-8. PubMed ID: 16217764
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
Simon I; Liu Y; Krall KL; Urban N; Wolfert RL; Kim NW; McIntosh MW
Gynecol Oncol; 2007 Jul; 106(1):112-8. PubMed ID: 17490732
[TBL] [Abstract][Full Text] [Related]
47. Glycomics analysis of serum: a potential new biomarker for ovarian cancer?
Leiserowitz GS; Lebrilla C; Miyamoto S; An HJ; Duong H; Kirmiz C; Li B; Liu H; Lam KS
Int J Gynecol Cancer; 2008; 18(3):470-5. PubMed ID: 17655680
[TBL] [Abstract][Full Text] [Related]
48. Serum CA125 level before the development of ovarian cancer.
Kobayashi H; Ooi H; Yamada Y; Sakata M; Kawaguchi R; Kanayama S; Sumimoto K; Terao T
Int J Gynaecol Obstet; 2007 Nov; 99(2):95-9. PubMed ID: 17643440
[TBL] [Abstract][Full Text] [Related]
49. Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4.
Nishida Y; Kohno K; Kawamata T; Morimitsu K; Kuwano M; Miyakawa I
Gynecol Oncol; 1995 Mar; 56(3):357-61. PubMed ID: 7705668
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer.
Rice GE; Edgell TA; Autelitano DJ
J Exp Clin Cancer Res; 2010 Jun; 29(1):62. PubMed ID: 20525245
[TBL] [Abstract][Full Text] [Related]
51. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.
Høgdall EV; Høgdall CK; Blaakaer J; Heegaard NH; Glud E; Christensen L; Bock JE; Nørgaard-Pedersen B; Wiik A; Kjaer SK
APMIS; 2002 Aug; 110(7-8):545-53. PubMed ID: 12390412
[TBL] [Abstract][Full Text] [Related]
52. Clinical analysis of chemo-resistance risk factors in endometriosis associated ovarian cancer.
Ren T; Sun TT; Wang S; Sun J; Xiang Y; Shen K; Lang JH
J Ovarian Res; 2018 May; 11(1):40. PubMed ID: 29843765
[TBL] [Abstract][Full Text] [Related]
53. Neutrophil-to-Lymphocyte Ratio in Ovarian Cancer Patients with Low CA125 Concentration.
Zhang H; Huo Q; Huang L; Cheng Y; Liu Y; Bao H
Biomed Res Int; 2019; 2019():8107906. PubMed ID: 31341906
[TBL] [Abstract][Full Text] [Related]
54. Screening Cuts Ovarian Cancer Mortality.
Cancer Discov; 2016 Feb; 6(2):OF1. PubMed ID: 26758578
[TBL] [Abstract][Full Text] [Related]
55. Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.
Pochechueva T; Chinarev A; Schoetzau A; Fedier A; Bovin NV; Hacker NF; Jacob F; Heinzelmann-Schwarz V
PLoS One; 2016; 11(10):e0164230. PubMed ID: 27764122
[TBL] [Abstract][Full Text] [Related]
56. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
[No Abstract] [Full Text] [Related]
57. Decreased serum level of thioredoxin 1 in female patients with pneumonia and its combinational use with haptoglobin for the specific diagnoses of pneumonia and lung cancer.
Cha MK; Kim IH
Pneumonia (Nathan); 2015; 6():18-25. PubMed ID: 31641575
[TBL] [Abstract][Full Text] [Related]
58. Usefulness of CA125 in the differential diagnosis of uterine adenomyosis and myoma.
Kil K; Chung JE; Pak HJ; Jeung IC; Kim JH; Jo HH; Kim MR
Eur J Obstet Gynecol Reprod Biol; 2015 Feb; 185():131-5. PubMed ID: 25577553
[TBL] [Abstract][Full Text] [Related]
59. Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection.
Skubitz APN; Boylan KLM; Geschwind K; Cao Q; Starr TK; Geller MA; Celestino J; Bast RC; Lu KH; Koopmeiners JS
Cancer Prev Res (Phila); 2019 Mar; 12(3):171-184. PubMed ID: 30709840
[TBL] [Abstract][Full Text] [Related]
60. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials.
Skates SJ
Int J Gynecol Cancer; 2012 May; 22 Suppl 1(Suppl 1):S24-6. PubMed ID: 22543916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
